Mark A. Socinski, MD

Mark A. Socinski, MD, discusses data from stage 1 of the phase 3 PRESERVE-003 trial (NCT05671510) in patients with squamous NSCLC.

Mark Socinski, MD, highlights Stage 1 PRESERVE-003 data showing chemotherapy-free gotistobart improved survival and durable responses vs docetaxel in previously treated metastatic squamous NSCLC.

In their concluding remarks, the experts highlight critical future directions and unmet needs in non-small cell lung cancer (NSCLC). A major focus is on improving lung cancer screening. They note that current screening rates are unacceptably low (~20%) and emphasize the need to better integrate it into primary care. Furthermore, they call for expanded screening criteria to include populations not currently eligible, such as never-smokers and light smokers, especially women, who are increasingly being diagnosed.

Experts discuss the critical factors for recommending adjuvant chemotherapy after surgery for early-stage non-small cell lung cancer (NSCLC). They confirm that lymph node involvement (N1 disease) is a clear indicator for offering platinum-based chemotherapy due to the higher risk of recurrence.

Experts emphasize the indispensable role of a multidisciplinary team (MDT) in managing non-small cell lung cancer (NSCLC). They highlight that complex cases, like the one discussed, demonstrate how knowledge evolves and how critical collaborative decision-making is for optimal patient outcomes.

Experts address the critical differences between pre-operative biopsies and post-operative surgical specimens for biomarker testing. They confirm that a surgical specimen is far more reliable, as it provides a larger, higher-quality sample, allowing a pathologist to select a more tumor-rich area for analysis. This was key in finally identifying the patient's RET fusion.

Experts discuss how the final pathology report, which included an RNA-based NGS test, definitively resolved the case by identifying a RET fusion. They highlight this finding as a critical justification for comprehensive biomarker testing, especially in never-smoker patients where initial results are negative.

Experts discuss how to manage a complex non-small cell lung cancer (NSCLC) case with ambiguous neuroendocrine markers and initially negative biomarker testing. They note that mixed biphenotypic tumors are not uncommon but present a diagnostic challenge.

Experts address a complex case of a never-smoker with early-stage non-small cell lung cancer (NSCLC). The diagnosis is complicated by ambiguous neuroendocrine markers on the biopsy, a PD-L1 score of 0%, and a negative NGS panel for common drivers, which is unusual for a never-smoker.

Experts discuss the critical importance of including RNA sequencing in comprehensive biomarker testing for non-small cell lung cancer (NSCLC). They highlight that while DNA-based NGS is foundational, it is insufficient for reliably detecting key gene fusions like RET and ROS1

Experts address managing recurrent non-small cell lung cancer (NSCLC) after definitive treatment with surgery and immunotherapy (IO). The experts outline a strategy based on the timing of recurrence.

Experts discuss treatment options for stage III non-small cell lung cancer (NSCLC) without actionable driver mutations and with a PD-L1 expression of 30%. The experts emphasize a multidisciplinary evaluation to decide between a surgical or non-surgical approach.

The oncologists delve into the specifics of which non-small cell lung cancer (NSCLC) patients to test. They recommend testing all non-squamous cases and, increasingly, squamous cases as well, especially those with a light smoking history, to ensure no actionable biomarker is missed.

The oncologists delve into the specifics of which non-small cell lung cancer (NSCLC) patients to test. They recommend testing all non-squamous cases and, increasingly, squamous cases as well, especially those with a light smoking history, to ensure no actionable biomarker is missed.

The oncologists delve into the specifics of which non-small cell lung cancer (NSCLC) patients to test. They recommend testing all non-squamous cases and, increasingly, squamous cases as well, especially those with a light smoking history, to ensure no actionable biomarker is missed.

Two expert oncologists discuss the critical role of comprehensive biomarker testing in non-small cell lung cancer (NSCLC). They emphasize that molecular testing is an essential part of the initial diagnosis, not an optional add-on, as it identifies specific mutations and fusions that dictate the most effective first-line treatment.

Drs Camidge and Socinski discussed the highlights of Dr Socinski's career trajectory and the personal influences that helped him arrive where he is today.

The panel examines which patient populations might benefit most from treatment with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd). Additionally, they explore potential sequencing strategies for these antibody-drug conjugates in second-line and later treatment settings.

Benjamin Levy, MD, compares the common toxicities associated with datopotamab deruxtecan (Dato-DXd), sacituzumab govitecan, and patritumab deruxtecan (HER3-DXd), and shares practical tips for managing these toxicities in the clinical setting to optimize patient care and minimize adverse effects.

Julia Rotow, MD, highlights and discusses other notable antibody-drug conjugate (ADC) data presented at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, providing insights into the potential impact of these findings on the evolving treatment landscape for non-small cell lung cancer (NSCLC).

Benjamin Levy, MD, provides an overview of the rationale and study design for the EVOKE-01 trial, which evaluates the efficacy and safety of sacituzumab govitecan in patients with non-small cell lung cancer who have experienced disease progression following treatment with platinum-based chemotherapy and checkpoint inhibitors.

Helena A. Yu, MD, initiates a discussion on the role of HER3 in the development of resistance to EGFR-targeted therapies. She also examines the HERTHENA-Lung01 study and analyzes the emerging data from this trial.

The panel explores promising novel therapies in the treatment landscape, focusing on new or recently presented data at the American Society of Clinical Oncology (ASCO) 2024 annual meeting, and share their insights on the potential impact of these therapies on future clinical practice.

Helena A. Yu, MD, examines the patient selection criteria for potentially using osimertinib monotherapy, osimertinib plus chemotherapy, or amivantamab combined with lazertinib in the first-line treatment of advanced EGFR-mutant non-small cell lung cancer.

Benjamin Levy, MD, initiates a discussion on the rationale behind using amivantamab and lazertinib as a first-line treatment for EGFR-mutant non-small cell lung cancer and reviews the recently presented efficacy and safety data from the MARIPOSA trial.

The panel discusses which patients with EGFR-mutant non-small cell lung cancer (NSCLC) are more likely to receive frontline treatment with either osimertinib monotherapy or the combination of osimertinib and chemotherapy, based on individual patient characteristics and preferences.

Helena A. Yu, MD, discusses her treatment strategy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing current guidelines and standard of care, while Zosia Piotrowska, MD, MHS, examines the key efficacy and safety findings from the FLAURA2 study, which evaluated first-line osimertinib combined with chemotherapy in patients with advanced EGFR-mutant NSCLC.

The panel examines the characteristics of patients with non-small cell lung cancer (NSCLC) without actionable alterations who might be the best candidates for frontline treatment with either sacituzumab govitecan or datopotamab deruxtecan (Dato-DXd) and identifies the persisting unmet needs for this patient population.